Next generation pneumococcal vaccines

Curr Opin Immunol. 2011 Jun;23(3):407-13. doi: 10.1016/j.coi.2011.04.002. Epub 2011 Apr 21.

Abstract

Currently licensed pneumococcal vaccines are based on the generation of antibodies to the pneumococcal polysaccharide, of which there are more than 90 different types. While these vaccines are highly effective against the serotypes included, their high cost and limited serotype coverage limit their usefulness worldwide, particularly in low resource areas. Thus alternative or adjunctive options are being actively pursued. This review will present these various approaches, including variations of the polysaccharide-protein conjugate strategy, protein-based strategies, and whole cell pneumococcal vaccines. The immunological basis for these different approaches is discussed as well.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Adaptive Immunity
  • Animals
  • Disease Models, Animal
  • Humans
  • Pneumococcal Vaccines / economics
  • Pneumococcal Vaccines / immunology*
  • Pneumococcal Vaccines / therapeutic use
  • Pneumonia, Pneumococcal / immunology*
  • Pneumonia, Pneumococcal / prevention & control*
  • Streptococcus pneumoniae / immunology*

Substances

  • Pneumococcal Vaccines